Protease Inhibitors + Dihydroergotamine MesylateContraindicated
CYP 3A4 inhibitors increase dihydroergotamine exposure; contraindicated per prescribing information.
Source: NLP:dihydroergotamine mesylate
Protease Inhibitors Interactions
29 interactions on record
Protease Inhibitors + Ezetimibe And SimvastatinContraindicated
Strong CYP3A4 inhibitors that increase simvastatin plasma levels, elevating risk of myopathy and rhabdomyolysis.
Source: NLP:ezetimibe and simvastatin
Protease Inhibitors + LovastatinContraindicated
Strong CYP3A4 inhibitors increase risk of myopathy by reducing lovastatin elimination.
Source: NLP:lovastatin
Protease Inhibitors + SimvastatinContraindicated
Strong CYP3A4 inhibitors that increase simvastatin plasma levels, elevating risk of myopathy and rhabdomyolysis.
Source: NLP:simvastatin
Protease Inhibitors + TriazolamContraindicated
Several HIV protease inhibitors are contraindicated with triazolam due to CYP 3A inhibition.
Source: NLP:triazolam
Concomitant use may increase concentration of cytotoxic metabolites and enhance toxicities of cyclophosphamide, including higher incidence of infections, neutropenia, and mucositis.
Source: NLP:cyclophosphamide
Protease inhibitors may inhibit CYP450 enzymes affecting amiodarone metabolism; potential for increased amiodarone exposure.
Source: NLP:amiodarone hydrochloride
OATP1B1/1B3 inhibitors increase brincidofovir AUC and Cmax, may increase adverse reactions. Monitor for elevations in transaminases, bilirubin, diarrhea, or GI events.
Source: NLP:brincidofovir
Strong CYP3A4 inhibitors like HIV protease inhibitors may increase bromocriptine plasma levels; caution advised when co-administering.
Source: NLP:bromocriptine mesylate
CYP3A4 inhibitors that increase carbamazepine plasma levels. Close monitoring of carbamazepine levels and dosage adjustment may be required.
Source: NLP:carbamazepine
May cause significant increases or decreases in plasma concentrations of estrogen and progestin.
Source: NLP:drospirenone and ethinyl estradiol
Significant changes (increase or decrease) in plasma concentrations of estrogen and progestin have been noted in some cases.
Source: NLP:drospirenone, ethinyl estradiol and levomefolate calcium and levomefolate calcium
Protease Inhibitors + Drospirenone/Ethinyl Estradiol/Levomefolate Calcium And Levomefolate CalciumModerate
May cause significant changes (increase or decrease) in plasma concentrations of estrogen and progestin.
Source: NLP:drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium
May reduce glucose-lowering effect of glimepiride, leading to worsening glycemic control.
Source: NLP:glimepiride
Protease Inhibitors + GlipizideModerate
May reduce the glucose-lowering effect of glipizide, leading to worsening glycemic control. Monitor closely.
Source: NLP:glipizide
May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.
Source: NLP:insulin aspart
May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.
Source: NLP:insulin aspart-szjj
May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
Source: NLP:insulin degludec
May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.
Source: NLP:insulin glargine
May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.
Source: NLP:insulin glulisine
May decrease blood glucose lowering effect; dose adjustment and increased glucose monitoring may be required.
Source: NLP:insulin human
May decrease blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.
Source: NLP:insulin lispro-aabc
Significant changes in plasma levels of estrogen and progestin have been noted with co-administration.
Source: NLP:levonorgestrel / ethinyl estradiol and ethinyl estradiol
Protease Inhibitors + MaravirocModerate
CYP3A inhibitors including protease inhibitors (except tipranavir/ritonavir) increase maraviroc concentration; dosage adjustment may be required.
Source: NLP:maraviroc
Significant changes (increase or decrease) in plasma progestin levels may occur with co-administration.
Source: NLP:medroxyprogesterone acetate
HIV protease inhibitors are potent CYP3A4 inhibitors that may increase mirtazapine concentrations. Caution should be exercised when coadministering.
Source: NLP:mirtazapine
May inhibit CYP450 enzymes, increasing amiodarone exposure and potential for interactions.
Source: NLP:nexterone (amiodarone hci)
May cause significant increases or decreases in plasma levels of estrogen and progestin, potentially decreasing contraceptive effectiveness.
Source: NLP:norethindrone acetate and ethinyl estradiol, ethinyl estradiol and ferrous fumarate
Caution should be exercised when using alpha 1 adrenergic receptor antagonists with oxymetazoline.
Source: NLP:oxymetazoline hydrochloride